Health Professional Radio - Podcast

The safe adoption of AI can benefit mammography departments as they strive to deliver on the goals of the national breast screening program. Dr. Christopher Austin, Chief Medical Officer at Kheiron Medical Technologies, discusses the challenges that face Australia’s breast screening programs and how AI can help address those challenges, learnings from the UK’s National Health System’s adoption of AI in breast screening, and how those learnings can benefit Australian radiologists and women. Dr. Christopher Austin serves as chief medical officer at Kheiron Medical Technologies where he contributes his extensive knowledge and expertise as a trained radiologist, epidemiologist, strategist and innovator with more than 20 years of combined clinical and industry expertise on a global level.  He is a recognized thought leader in artificial intelligence and radiology, having worked with leading academic organizations to develop deep learning algorithms.  Prior to joining Kheiron, Dr. Austin held healthcare m

Branko Kolvek, SVP of Operations at Pager, discusses the company’s virtual care collaboration platform while exploring the differences between telehealth and virtual care. He’ll also provide insight into how digital platforms can control healthcare costs, limit telehealth overutilization, and improve the patient experience. Offered through health plans, Pager’s platform provides access to a care coordination team and combines omni-channel communications, artificial intelligence, and machine learning to deliver high-touch concierge services that guide patients along the entire care path, from chat and triage, to scheduling, customer service, e-prescribing, and follow-up care. Branko Kolvek is Senior Vice President of Operations at Pager, a virtual care collaboration platform that offers whole-person healthcare and hi-tech, hi-touch concierge services to connect patients with the care and services they need. In his current role, Mr. Kolvek oversees operational processes and care services to drive performance an

Nancy Di Dia, Executive Director, Chief Diversity & Inclusion Officer & Head, US DICE at Boehringer Ingelheim USA discusses her 15 years as a D&I officer, her personal history, and how she nurtured the development of the D&I programs at a pharmaceutical industry giant. She shares her learnings on how to build sustainable change over time. Nancy Di Dia is Executive Director, Chief Diversity & Inclusion Officer & Head, US DICE at Boehringer Ingelheim USA. She brings more than 25 years of change and social experience in overall management, leadership and cultural change in the corporate world. Her experience has spanned financial services and healthcare. At Boehringer Ingelheim Nancy has responsibility for leading a culture of diversity, inclusion, engagement and belonging within BI’s Animal Health, Biopharma and Human Pharma business units. In addition, Nancy is an (ICF) International credentialed and certified PCC Executive Coach with a focus on finding impactful ways to engage the brai

Co-founder Lawrence Kosick discusses GetSetUp, a company founded in 2019 to provide an online learning platform for older adults with classes taught by older adults. In recent months, GetSetUp has announced partnerships with various state government agencies to address issues associated with the pandemic, including a partnership with The New York State Office for the Aging (NYSOFA). Older adults in New York now have access to GetSetUp’s 50,000 classes, featuring more than 300 different course options developed by and for older adults. The GetSetUp curriculum and community are designed to combat social isolation and promote independence through live, interactive classes and online connectivity with a community of more than 650,000 older adult learners from more than 160 countries around the globe. Neil Dsouza and Lawrence Kosick were trail running partners and seasoned technology executives who co-founded GetSetUp, a live, interactive learning platform for older adults who want to learn new skills, connect wit

Over the past year, many people have missed or postponed medical appointments due to the pandemic.  For people with chronic conditions like multiple sclerosis (MS), a missed treatment or delayed care could lead to disease progression and debilitating relapses.  Dr. Mitzi Joi Williams, MD, MS expert and board-certified neurologist discusses implications surrounding missed doctor's appointments, including irreversible disease progression, the importance of continuing treatment, and of identifying disease progression early.  She urges people living with MS to continue seeking care or catch up on missed or postponed doctor visits due to the pandemic. Dr. Mitzi Joi Williams is a Board-Certified neurologist and Fellowship trained Multiple Sclerosis Specialist. Dr. Mitzi is passionate about educating and empowering people affected by MS to understand the disease process and the goals of treatment. She is a sought-after consultant, speaker, researcher and author. She has expertise in understanding MS i

Dr. Sammy Elmariah, Director, Interventional Cardiology Research at Massachusetts General Hospital discusses his recent research "Transfemoral Tricuspid Valve Replacement In Patients With Tricuspid Regurgitation: 30-day Results Of The Triscend Study" which was recently presented at the 2021 American College of Cardiology's annual scientific meeting. Dr. Sammy Elmariah graduated from the University of Pennsylvania School of Medicine and completed his internal medicine residency training at the Hospital of the University of Pennsylvania. He subsequently served as Chief Medical Resident at Lankenau Hospital. Dr. Elmariah completed his fellowship in cardiovascular medicine at the Mount Sinai Hospital in New York where he also served as Chief Fellow. While a fellow, he also completed a Masters in Public Health at the Harvard School of Public Health. Dr. Elmariah completed further fellowship training in interventional cardiology and structural heart disease at the Massachusetts General Hospital. Currently, Dr. Elma

Dr. Ellie Stang, a board-certified pediatrician and founder and CEO of ProgenyHealth, a healthcare company that applies evidence-based care management solutions to improve outcomes for premature and medically complex newborns, discusses how American women die in childbirth at a higher rate than in any other developed country, social determinants of health (SDOH), and how payers can effectively manage high-cost scenarios that require specialized expertise. #ProgenyHealth #PrematureNewborns #MedicallyComplexNewborns As the Founder and CEO of ProgenyHealth, she is responsible for the strategic direction of the company. This entails being ultimately responsible for day-to-day management decisions and for implementing the Company's long and short term plans. Prior to founding ProgenyHealth, Dr. Stang was a Regional Medical Director at a large managed Medicaid plan responsible for overseeing the medical management of their pediatric membership. Before entering managed care, she enjoyed many years in private practic

Today, up to 60% of elderly persons develop delirium during hospitalization for an injury or unintentional fall. Dr. Franco Garcia, geriatric medicine specialist at Massachusetts General Hospital discusses data presented during the 2021 American Geriatrics Society’s Annual Meeting, that shows nutrition may be a modifiable risk factor for hospitalized, elderly orthopedic trauma patients. He shares key findings from his study, "Nutritional status is associated with new-onset delirium in elderly, acute care, orthopedic trauma patients: A single-center observational study". #AGS2021 Dr. Esteban Franco Garcia is a Geriatric Medicine Specialist in Boston, Massachusetts. He graduated with honors in 2003. Having more than 18 years of diverse experiences, especially in Geriatic Medicine, Internal Medicine, Dr. Esteban Franco Garcia affiliates with Massachusetts General Hospital, cooperates with many other doctors and specialists in medical group Massachusetts General Physicians Organization Inc.

Dr. Michael McCullar, CEO, and Dr. Hong Tang, Chief Medical Officer at OnQuality Pharmaceuticals, a clinical stage pharma company pioneering the discovery and development of targeted cancer supportive care therapies that address cancer treatment-related toxicities at the molecular level, discuss the company's lead pipeline candidate, OQL011, the first targeted treatment for the severe cancer med side effect Hand Foot Skin Reaction (HFSR). OQL011 is currently in Phase 2 study at onco-dermatology clinics across the country. It is a topical ointment that can be applied to the hands and feet, acting locally to restore VEGFR signaling while avoiding any interference with the main cancer med mechanism of action. Michael McCullar is the Chief Executive Officer of OnQuality Pharmaceuticals. He has more than 20 years of pharmaceutical experience in strategic planning and development, drug discovery and operation, business development and commercial operation. Previously he served as Chief Operating Officer at Tolero P

Newly appointed Chief Medical Officer of HD Medical, Inc., Shaun Setty, MD, discusses their flagship product, HD Steth, an FDA cleared Intelligent Stethoscope with ECG and PCG in a single device.  It allows providers to capture unsurpassed sound fidelity enhanced by visualization on the HD Steth Android or Apple iOS app. He also talks about HD Medical’s new HealthyU device, an all-in-one remote patient monitor, to be launched in the US in January 2022. Dr. Setty is a cardiothoracic surgeon in Los Angeles, CA, with over 13 years of experience in pediatric and adult congenital cardiac surgery. Dr. Setty is triple-board certified in surgery, thoracic surgery and congenital heart surgery, with experience in all aspects of cardiac surgery. Dr. Setty began his medical education at the Medical College of Ohio, where he graduated with Alpha Omega Alpha honors, followed by a general surgery residency at Oregon Health & Science University. He went on to complete his cardiothoracic surgery training at the Unive

Returning guest, Dr. Andrew Chan, MD, MPH, Gastroenterologist, Chief, Clinical and Translational Epidemiology Unit, Director of Cancer Epidemiology, Massachusetts General Cancer Center discusses his recent research "Associations Between Screening Lower Endoscopy and Colorectal Cancer Incidence in Younger Adults", which was recently presented at the 2021 Digestive Disease Week annual scientific meeting. Andrew T. Chan, M.D., M.P.H. is a Professor of Medicine at Harvard Medical School (HMS), Chief of the Clinical and Translational Epidemiology Unit, and the Program Director for gastroenterology training at Massachusetts General Hospital (MGH).  As a clinical gastroenterologist, Dr. Chan specializes in familial gastrointestinal cancer syndromes and cancer prevention. #DDW21 #LowerEndoscopy #ColorectalCancer

Rich Kreuger, Co-founder and CEO of Hospital IQ, the leading provider of predictive hospital operations software, discusses how the company provides an operations management software platform that uses AI to anticipate and direct actions, enabling health systems to achieve and sustain peak operational performance.  He talks about the importance of streamlining provider operations post-pandemic and the value of building tech with scalability. As CEO of Hospital IQ, Rich uses technology to limit waste in the healthcare industry and help hospitals provide outstanding care to as many patients as possible. He has a proven track record of developing and commercializing new technologies, and has been directly involved in software products that continue to solve major industry problems and generate over $100m per year in revenue. Prior to joining Hospital IQ, Rich was the founder and CEO of DynamicOps, a cloud automation software company that was acquired by VMware in 2012. He also held executive roles at compan

Anne Quinn Young, MPH, Brand President of the MMRF discusses CureCloud, their latest platform designed to provide myeloma patents with their own genomic profile while building a database that combines genomic insights with clinical data to identify trends and support further developments. The CureCloud mission is to find and develop cures for all myeloma patients based on the fact that all patients can contribute to cures and each patient can benefit from the masses. Anne Quinn Young, MPH, is the Brand President at the MMRF and is responsible for overseeing the strategy and execution of the organization’s marketing, communications, patient engagement, and fundraising efforts in support of the organization’s mission to accelerate precision medicine and a cure for every patient. Anne has been named to the PharmaVoice 100, and represents the MMRF on a number of working groups and committees including the Direct-to-Patient (DTP) solutions team at the Harvard Business School (HBS) Kraft Precision Medicine Accelera

John Whelan, President, CEO and Director of Inhalon Biopharma, a start-up immunotherapy company developing an inhaled “muco-trapping” antibody platform  for treating a variety of acute respiratory infections, discusses the award of a $7 million government contract from the U.S. Army Medical Research & Development Command (USAMRDC) to conduct a placebo-controlled Phase 1/2a study of the treatment in COVID-19 outpatients.  Inhalon’s treatment, IN-006, is a potent, neutralizing monoclonal antibody designed to trap pathogens like COVID-19 in airway mucus and clear them from the airways in minutes.  This technology offers a more immediate and scalable way of treating respiratory infections than current treatment options. John has over 20 years of experience leading venture-backed and public biotech companies. He has worked in early and late-stage companies taking products from discovery through NDA submission. He has contributed to the growth of these companies by building skilled, effective man

Returning guest, Dr. Kathryn Lang, VP of Outcomes and Evidence at Guardant Health discusses the recent data shared at the 2021 American Society of Clinical Oncology (ASCO) on the investigational blood-based LUNAR-2 assay.  This data shows that it offers a high sensitivity in detecting colorectal cancer (CRC) in asymptomatic patients. This is particularly important now that the U.S. Preventive Services Task Force announced it has lowered the age for CRC screening from 50 to 45. Dr. Kathryn Lang is a board certified hemato-oncologist, who completed clinical training in London, UK. With a strong focus on outcomes research throughout her career and over 50 publications, Dr. Lang moved to an industry role with Pfizer in 2016 where she led the global data science initiatives and developed regulatory grade observational research within Pfizer Oncology. She moved to her current role with Guardant Health in 2018 where she is VP of Outcomes and Evidence focusing on early detection of cancer and applied health econ

Dr. Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics at the Lombardi Comprehensive Cancer Center of Georgetown University discusses updated results from a study of patients with RET fusion–positive NSCLC enrolled in the ARROW study, evaluating the efficacy of GAVRETO (pralsetinib) that was presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Dr. Stephen V. Liu, MD, is an Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics at the Lombardi Comprehensive Cancer Center of Georgetown University.A Pittsburgh native, Dr. Liu graduated cum laude at Johns Hopkins University with a major in Biology and a minor in Film and Media Studies, before receiving his M.D. at the University of Maryland. He completed his Internal Medicine training at the University of Pennsylvania and a dual fellowship in Hematology and Oncology at the University of Southern California, after

The COVID-19 pandemic changed how consumers access care and brought health care payers and providers together to better enable providers to care for patients when they needed it most. Angie Meoli, Senior Vice President of Network Strategy and Provider Experience at Aetna, a CVS Health company, talks about some of the trends that emerged during the COVID-19 pandemic and will continue after the pandemic ends. Angela (Angie) Meoli is Senior Vice President, Head of Network Strategy and Provider Experience at Aetna, a CVS Health company. She leads network strategy and management, including strategic initiatives for achieving growth, affordability, product and local market objectives, for all medical and specialty lines of business. Ms. Meoli also oversees Aetna’s provider services organization with a focus on continuously improving the provider experience. Previously, Ms. Meoli was Aetna’s local market president for the Mid-Atlantic Territory, where she was responsible for approximately two million members and mor

Returning guest, Dr. Andrew Greenspan, Vice President of Immunology Medical Affairs at Janssen discusses recent data from the Phase 3b SEAVUE study, the first head-to-head study of biologic therapies in patients with Crohn’s disease, evaluating the safety and efficacy of STELARA® (ustekinumab) compared with adalimumab through one year of treatment in biologic-naïve patients. These data were presented at this year’s Digestive Disease Week (DDW) Virtual 2021, where Janssen Immunology presented 20 abstracts in total from the company’s gastroenterology portfolio and pipeline. As Vice President of Immunology Medical Affairs, Andrew Greenspan, M.D., is responsible for leadership and oversight of Immunology Medical Affairs activities supporting REMICADE® (infliximab), SIMPONI® (golimumab), SIMPONI ARIA® (golimumab for infusion), STELARA® (ustekinumab) and TREMFYA® (guselkumab) for a wide range of diseases, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis and psoriasis. #Immunology #CrohnsDisease #

Tony Ezell, President, North America and Chief Marketing Officer of BD (Becton, Dickinson and Company), discusses how BD and USA Track & Field (USATF) are working together to help get athletes back on the track safely through the use of rapid COVID-19 testing with the BD Veritor™ Plus System. In addition to helping athletes get safely back to competition as the official COVID-19 testing sponsor of USATF, the BD Veritor™ Plus System is helping the public get back on track with their normal lives. Ezell shares how BD has been at the forefront of the COVID-19 response, and how it will continue to support our continued return to normalcy. Tony Ezell serves as the president of North America and chief marketing officer for BD (Becton, Dickinson and Company), a leading global medical technology company headquartered in Franklin Lakes, New Jersey. In this role, he leads the U.S. and Canada regions and the Global Marketing organization and is responsible for an integrated commercialization approach to how we addre

Amyloidosis is a serious health condition that often goes undiagnosed – leading to improper management and heavy symptom burden on patients and families. New research presented at the 2021 American Geriatrics Society’s annual meeting shows the benefit of early diagnosis, the role of genetics, and the benefit of an amyloid specialist. Dr. Sharon Levine, MD, AGSF, Section Head, Geriatric Medicine, Division of Palliative Care and Geriatric Medicine in Boston, MA, and Andrea Kurkul, RP, Nurse Practitioner in Boston, MA, are here to discuss these findings and their study, "A Puzzle Finally Solved".    Dr. Sharon Levine, MD is a Geriatric Medicine Specialist in Boston, MA and has over 37 years of experience in the medical field.  She graduated from Yeshiva U, College of Medicine medical school in 1984.  She is affiliated with Boston Medical Center. #AGS2021 #Amyloidosis